Botulinum Toxin in Spasticity Management—from Established Practices to Emerging
A special issue of Toxins (ISSN 2072-6651). This special issue belongs to the section "Bacterial Toxins".
Deadline for manuscript submissions: 30 November 2025 | Viewed by 52
Special Issue Editors
Interests: physical medicine; rehabilitation; botulinum toxin: spasticity; movement disorders; neurorehabilitation
Interests: rehabilitation medicine; spasticity; ultrasound; botulinum toxin; injection; neurorehabilitation; neurological diseases; mobility limitation; physical functional performance
Special Issue Information
Dear Colleagues,
This Special Issue, titled “Botulinum Toxin in Spasticity Management—from Established Practices to Emerging”, aims to provide a comprehensive examination of both time-tested clinical protocols and the latest innovations in treatment. Contributions are invited to explore the extensive body of research validating the efficacy of botulinum toxin in reducing muscle hyperactivity and improving functional outcomes, alongside emerging strategies that incorporate advanced technologies. In particular, the integration of artificial intelligence—through approaches such as predictive modeling for dose optimization and algorithm-based personalization of treatment regimens—is an emerging trend under investigation to enhance precision in spasticity management. Additional topics of interest include early detection methods, advanced imaging techniques, and digital health solutions that can further refine diagnosis and intervention strategies.
This Special Issue welcomes original research, randomized controlled trials, systematic reviews, meta-analyses, and detailed case studies in human populations.
Dr. Stefania Spina
Dr. Salvatore Facciorusso
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Toxins is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- botulinum toxin
- spasticity
- efficacy
- artificial intelligence
- precision medicine
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
